Communiqués 4basebio PLC

Actions

4BB

GB00BMCLYF79

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 17:35:16 29/09/2026			Varia. 5j.	Varia. 1 janv.
562,50 ^GBX	0,00%		0,00%	-8,54%

28/09	4Basebio plc et TriLink BioTechnologies s’associent pour faire progresser le programme de thérapie cellulaire de phase I d’un groupe pharmaceutique multinational	CI
28/09	4basebio PLC : RBC Capital Markets favorable sur le dossier	ZM

Communiqués

14:16	4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program	AQ
14:16	4basebio PLC - Half-year Report for the six months ended 30 June 2026	AQ
28/09	4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program	AQ
28/09	4basebio Plc - Half-year Report	PR
28/09	4basebio Plc - 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program	PR
07/09	4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine	PR
26/08	4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing	GL
26/08	4basebio Plc - 4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing	PR
22/07	4basebio Plc - Grant of Options & Director/PDMR Dealing	PR
08/07	4basebio Plc - Director Appointment	PR
30/06	4basebio Plc - Result of AGM & Issue of Options	PR
16/06	4basebio Plc - Notice of Investor Presentation	PR
15/06	4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board	AQ
15/06	4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board	PR
05/06	4basebio Plc - Notice of Annual General Meeting	PR
22/05	4basebio Plc - Director Dealing	PR
20/05	Final Results and Notice of AGM	AQ
20/05	4basebio Plc - Final Results and Notice of AGM	PR
20/05	4basebio Plc - 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial	PR
14/05	4basebio Announces Appointment of Chief Financial Officer and Board Changes	AQ
14/05	4basebio Plc - Appointment of Chief Financial Officer and Board Changes	PR
11/05	4basebio Launches Enzymatic ssDNA Platform	AQ
11/05	4basebio Plc - 4basebio Launches Enzymatic ssDNA Platform	PR
31/03	4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK	AQ
31/03	4basebio Plc - Lease of Manufacturing Facility	PR